Drug Resistance Inhibition in Treating Women With Recurrent or Metastatic Breast Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Some tumors become resistant to chemotherapy drugs. Combining PSC 833 with a
chemotherapy drug may reduce resistance to the drug, and allow the tumor cells to be killed.
PURPOSE: Phase II trial to study the effectiveness of PSC 883 and paclitaxel in treating
women who have recurrent or metastatic breast cancer.